SG11201403891SA - Purification of flaviviruses - Google Patents

Purification of flaviviruses

Info

Publication number
SG11201403891SA
SG11201403891SA SG11201403891SA SG11201403891SA SG11201403891SA SG 11201403891S A SG11201403891S A SG 11201403891SA SG 11201403891S A SG11201403891S A SG 11201403891SA SG 11201403891S A SG11201403891S A SG 11201403891SA SG 11201403891S A SG11201403891S A SG 11201403891SA
Authority
SG
Singapore
Prior art keywords
flaviviruses
purification
Prior art date
Application number
SG11201403891SA
Inventor
Sophia Mundle
Stephen Anderson
Original Assignee
Sanofi Pasteur Biologics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur Biologics Llc filed Critical Sanofi Pasteur Biologics Llc
Publication of SG11201403891SA publication Critical patent/SG11201403891SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/10—Cross-flow filtration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24133—Use of viral protein as therapeutic agent other than vaccine, e.g. apoptosis inducing or anti-inflammatory
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24151—Methods of production or purification of viral material

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Water Supply & Treatment (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11201403891SA 2012-01-09 2013-01-08 Purification of flaviviruses SG11201403891SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261584461P 2012-01-09 2012-01-09
PCT/US2013/020686 WO2013106337A1 (en) 2012-01-09 2013-01-08 Purification of flaviviruses

Publications (1)

Publication Number Publication Date
SG11201403891SA true SG11201403891SA (en) 2014-08-28

Family

ID=48781838

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201510800PA SG10201510800PA (en) 2012-01-09 2013-01-08 Purification of flaviviruses
SG11201403891SA SG11201403891SA (en) 2012-01-09 2013-01-08 Purification of flaviviruses

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201510800PA SG10201510800PA (en) 2012-01-09 2013-01-08 Purification of flaviviruses

Country Status (6)

Country Link
US (1) US20150030565A1 (en)
EP (1) EP2802650A4 (en)
AU (1) AU2013208187B2 (en)
CA (1) CA2896931A1 (en)
SG (2) SG10201510800PA (en)
WO (1) WO2013106337A1 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10207225B2 (en) 2014-06-16 2019-02-19 Emd Millipore Corporation Single-pass filtration systems and processes
WO2015195453A2 (en) 2014-06-16 2015-12-23 Emd Millipore Corporation Methods for increasing the capacity of flow-through processes
CN110756051B (en) 2014-06-25 2022-11-04 Emd 密理博公司 Filter element, tangential flow filtration system, method of producing a feed screen
WO2016033546A1 (en) 2014-08-29 2016-03-03 Emd Millipore Corporation Single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
KR102061553B1 (en) 2014-08-29 2020-02-11 이엠디 밀리포어 코포레이션 Processes for filtering liquids using single pass tangential flow filtration systems and tangential flow filtration systems with recirculation of retentate
EP3353193A4 (en) * 2015-09-22 2019-04-03 Sanofi Pasteur Biologics, LLC Purification of respiratory syncytial virus
EA202090967A1 (en) * 2017-10-16 2020-08-12 Серум Инститьют Оф Индия Прайват Лимитед STABLE VACCINE COMPOSITIONS INCLUDING, IN PARTICULAR, LIVING ATTENUATED RECOMBINANT FLAVIVIRUS, AND THEIR PREPARATION PROCESS
JP2021528999A (en) * 2018-07-04 2021-10-28 プロバイオジェン アーゲー Envelope virus purification method
US20240076631A2 (en) 2020-02-27 2024-03-07 Takeda Vaccines, Inc. Method for removing host cell dna from virus preparation
GB202215814D0 (en) * 2022-10-26 2022-12-07 Cytiva Bioprocess R & D Ab A chromatography device, system, and use thereof for analytic separation

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889632A (en) 1987-12-10 1989-12-26 Ceskoslovenska Akademie Ved Macroporous polymeric membranes for the separation of polymers and a method of their application
EP0777725B1 (en) 1994-08-23 2001-04-04 Bia Separations D.O.O. Process and device for the rapid separation and/or conversion of substrates
US6962708B1 (en) 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
US6207439B1 (en) * 1997-03-25 2001-03-27 Center For Disease Control Purification of Japanese encephalitis virus
DE69927792T2 (en) 1998-02-27 2006-07-20 Bia Separations D.O.O. CHROMATOGRAPHIC DEVICE
AU2001281906A1 (en) 2000-06-27 2002-01-08 Bia Separations D.O.O. A chromatography material and a process of manufacturing that material
US20040259224A1 (en) 2002-05-31 2004-12-23 Farshad Guirakhoo Tetravalent Dengue vaccines
DK1869171T4 (en) * 2005-04-11 2016-01-18 Crucell Holland Bv Virus cleaning using ultrafiltration
US8124398B2 (en) * 2005-04-24 2012-02-28 Sanofi Pasteur Biologics Co. Recombinant flavivirus vaccines
WO2006122964A1 (en) * 2005-05-19 2006-11-23 Crucell Holland B.V. Methods for the production of a whole-inactivated west nile virus vaccine
JP5538729B2 (en) 2006-02-27 2014-07-02 ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム Mock infectious flaviviruses and their use
EP1878791A1 (en) * 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
RU2009105099A (en) 2006-07-14 2010-08-27 Санофи Пастер Байолоджикс Ко. (Us) CONSTRUCTION OF RECOMBINANT VIRAL VACCINES BY DIRECT TRANSPOSION-MEDIATED INSERATION OF ALIEN IMMUNOLOGICAL DETERMINANTS IN VECTOR VIRUS PROTEINS
WO2008094674A1 (en) * 2007-01-31 2008-08-07 Sanofi Pasteur Biologics Co. Recombinant bicistronic flavivirus vectors
EA201591888A1 (en) * 2008-03-14 2016-05-31 Санофи Пастер Байолоджикс Ко. REPLICATION-DEFECT VACCINES AND VACCINE VECTORS AGAINST FLAVIVIRUSS
US20120128713A1 (en) 2009-03-16 2012-05-24 Sanofi Pasteur Limited Replication-Defective Flavivirus Vaccine Vectors Against Respiratory Syncytial Virus
US20110142863A1 (en) * 2009-12-16 2011-06-16 Millipore Corporation Flow through purification processes for large biomolecules

Also Published As

Publication number Publication date
WO2013106337A1 (en) 2013-07-18
US20150030565A1 (en) 2015-01-29
AU2013208187A1 (en) 2014-07-24
AU2013208187B2 (en) 2018-07-12
EP2802650A1 (en) 2014-11-19
SG10201510800PA (en) 2016-01-28
EP2802650A4 (en) 2015-09-30
CA2896931A1 (en) 2013-07-18

Similar Documents

Publication Publication Date Title
IL287057A (en) Purification of iduronate-2 sulfatase
EP2826473A4 (en) Novel use of patchoulol
SG11201403891SA (en) Purification of flaviviruses
ZA201406082B (en) Use of ccr3-inhibitors
EP2917314A4 (en) Composition of oligomerate
IL263162B (en) Purification of cystathionine beta-synthase
IL236312A0 (en) Preparation of 18f-fluciclovine
EP2881113A4 (en) New application of pogostone
HK1202053A1 (en) Treatment of liver conditions
SG11201406800UA (en) Purification of air
PL2888228T3 (en) Inhibitors of cd40-traf6 interaction
EP2892529A4 (en) Uses of (-)-perhexiline
SG11201504201RA (en) Purification of x-ray contrast agents
GB201207907D0 (en) Treatment of depression
IL233740A0 (en) Treatment of liver conditions
TWM433525U (en) Structure of calorifier